Speaker(s): 

Cameron Hayes, MS, CGC-Genetic Counselor, Geisinger (Has nothing to disclose)

Brendan Carry, MD-Cardiology Physician, Geisinger (Has disclosed the following: 1. Pfizer ["Speakers Bureau","Consultant/Advisor"] 2. AstraZeneca ["Speakers Bureau","Consultant/Advisor"] 3. Alnylam ["Speakers Bureau","Consultant/Advisor","Research Grant"] 4. Daxor ["Speakers Bureau","Consultant/Advisor"])

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the clinical manifestations of Hereditary Transthyretin Amyloidosis

• Discuss current state of screening, prevention, and treatment of patients with TTR pathogenic/likely pathogenic variants

• Review TTR+ MyCode cases

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Adam Buchanan, MS, MPH, LCGC, Juliann Savatt, MS, LCGC, Melissa Kelly, MS, LCGC, Marc Williams, MD, and Cara McCormick, MPH have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Dean Parry, RPh and Katie Ritz, BS, RRT-NPS

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None